The Effectiveness Comparison of Salmeterol/Fluticasone Propionate and Formoterol Fumarate/Budesonide on Level of Asthma Control in Moderate Persistent Asthma
DOI:
https://doi.org/10.36497/05wkkx23Keywords:
Effectiveness Comparison, Salmeterol/Fluticasone Propionate, Formoterol Fumarate/Budesonide, Asthma Control Level, Moderate Persistent AsthmaAbstract
Background: Asthma is a prevalent chronic respiratory disease, affecting approximately 1–18% of the population worldwide. Despite its high prevalence, a substantial proportion of patients have partially controlled asthma, and limited data on the level of asthma control remain a significant concern.
Methods: This study aimed to compare the effectiveness of salmeterol/fluticasone propionate and formoterol fumarate/budesonide in achieving asthma control levels according to the ACQ-GINA criteria. A retrospective cohort study was conducted using 61 medical records from January 2017 to December 2019. Patients with moderate persistent asthma received either salmeterol/fluticasone propionate or formoterol fumarate/budesonide for at least three months. Statistical analysis was performed using Fisher’s exact test.
Results: A total of 61 patients were included. Most patients had partially controlled asthma (70.5%), followed by well-controlled (19.7%) and uncontrolled asthma (9.8%). No statistically significant difference in asthma control was observed between the two treatment groups (P = 0.057).
Conclusion: Within the limitations of this retrospective cohort study, no statistically significant difference in asthma control was observed between salmeterol/fluticasone propionate and formoterol fumarate/budesonide.
Downloads
References
1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2023.
2. American Lung Association. Asthma trends brief: Asthma trends and burden [Internet]. 2023 [cited 2023 Sep 9]. Available from: https://www.lung.org/research/trends-in-lung-disease/asthma-trends-brief/trends-and-burden
3. Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: Toward a better understanding. Asia Pac Allergy. 2014;4(2):75–85.
4. Kementerian Kesehatan Republik Indonesia. Hasil utama riset kesehatan dasar tahun 2018. Kementrian Kesehatan Republik Indonesia. 2018.
5. Centers for Disease Control and Prevention. Uncontrolled Asthma Among Adults, 2019. 2019.
6. Gold LS, Thompson P, Salvi S, Faruqi RA, Sullivan SD. Level of asthma control and health care utilization in Asia-Pacific countries. Respir Med. 2014;108(2):271–7.
7. O’Byrne PM, Reddel HK, Eriksson G, Östlund O, Peterson S, Sears MR, et al. Measuring asthma control: A comparison of three classification systems. European Respiratory Journal. 2010;36(2):269–76.
8. Soulele K, Macheras P, Karalis V. On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches. Pulm Pharmacol Ther. 2018;48:168–78.
9. Albataineh E, Al-Zayadneh E, Al-Shagahin H, AL Soloman A, Altarawneh A, Aldmour I. Asthma control and its predictive factors in adult asthma patients. J Clin Med Res. 2019;11(12):807–17.
10. Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–9.
11. Adachi M, Hozawa S, Nishikawa M, Yoshida A, Jinnai T, Tamura G. Asthma control and quality of life in a real-life setting: A cross-sectional study of adult asthma patients in Japan (ACQUIRE-2). Journal of Asthma. 2019;56(9):1016–25.
12. Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS/LABA: A real-world study. Journal of Asthma. 2019;56(3):332–40.
13. Postma DS. Gender differences in asthma development and progression. Gend Med. 2007;4(Suppl B):S133-46.
14. Mulyanto J, Kringos DS, Kunst AE. The accuracy of self-report versus objective assessment for estimating socioeconomic inequalities in disease prevalence in Indonesia. Int J Public Health. 2019;64(8):1233–41.
15. Cheng SL, Ho ML, Lai YF, Wang HC, Hsu JY, Liu SF, et al. Budesonide/formoterol anti-inflammatory reliever and maintenance or fluticasone propionate/ salmeterol plus as-needed, short-acting β2 agonist: Real-world effectiveness in patients without optimally controlled asthma (react) study. Drug Des Devel Ther. 2020;14:5441–50.
16. Kuna P. Treatment comparison of budesonideformoterol with salmeterolfluticasone propionate in adults aged ≥16 years with asthma: Post hoc analysis of a randomized, double-blind study. Clin Drug Investig. 2010;30(9):565–79.
17. Bateman ED, Busse W, Pedersen SE, Bousquet J, Huang S, Zhou X, et al. Global Initiative for Asthma 2016–derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysis. Annals of Allergy, Asthma and Immunology. 2019;123(1):57–63.
18. Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. Journal of Allergy and Clinical Immunology. 2007;119(2):344–50.
19. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392–7.
20. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405–11.
Published
Issue
Section
License
Copyright (c) 2026 Riska Resti, Amira Permatasari Tarigan, Andika Pradana, Arlinda Sari Wahyuni
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
